Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
08 Junho 2023 - 10:00AM
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that
is reimagining therapeutic delivery, today announced that it will
present preclinical data on oral delivery of a GLP-1 receptor
agonist with its BioJet systemic oral delivery platform in a short
oral discussion at the 59th annual meeting of the European
Association for the Study of Diabetes, to be held October 2–6, 2023
in Hamburg, Germany.
Details of the presentations are as follows:
Abstract Title: |
Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1
Receptor Agonist Delivered through the BioJet™ Biotherapeutic
Delivery Platform in Swine |
Presentation
No: |
635 |
Discussion
Session: |
SO 44 Novel Incretins |
Date: |
Tuesday, October 3, 2023, 13:45
to 14:45 CEST |
Presenting
Author: |
Shaoying Nikki Lee, PhD,
Director, Clinical and Translational Science, Biora Therapeutics,
Inc. |
|
|
Abstracts will be published on the EASD website on July 1, 2023.
Short oral presentations are embargoed until 12:30 CEST on October
3, 2023. Details of the presentation will also be made available on
the Biora Therapeutics website following the meeting.
About the BioJet™ Systemic Oral Delivery
PlatformBiora's BioJet systemic oral therapeutics platform
uses an ingestible capsule for needle-free, oral delivery of large
molecules designed to achieve systemic bioavailability and replace
injection for better management of chronic diseases.
The BioJet platform uses an ingestible device designed to
transit through the digestive system and activate in the small
intestine, where liquid jets deliver drug directly into the
intestinal tissue for uptake into systemic circulation. The BioJet
device is approximately the size of a multivitamin and is designed
to autonomously deliver a wide range of large molecules, such as
proteins, peptides, and nucleic acids, in liquid formulation up to
400µL.
Biora is developing multiple molecules for delivery via the
BioJet platform, including BT-002, a drug-device combination
consisting of a variant of adalimumab delivered via the BioJet
device for the treatment of inflammatory conditions, and BT-200,
which consists of a GLP-1 receptor agonist delivered via the BioJet
device for the treatment of type 2 diabetes. The company is
currently advancing preclinical development of both programs.
About Biora TherapeuticsBiora Therapeutics is
the biotech company that is reimagining therapeutic delivery. By
creating innovative smart pills designed for targeted drug delivery
to the GI tract, and systemic, needle-free delivery of
biotherapeutics, the company is developing therapies to improve
patients’ lives.
Biora is focused on development of two therapeutics platforms:
the NaviCap™ targeted oral delivery platform, which is designed to
improve outcomes for patients with inflammatory bowel disease
through treatment at the site of disease in the gastrointestinal
tract, and the BioJet™ systemic oral delivery platform, which is
designed to replace injection for better management of chronic
diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development and clinical
efforts, are forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,”
“might,” “will,” “objective,” “intend,” “should,” “could,” “can,”
“would,” “expect,” “believe,” “design,” “estimate,” “predict,”
“potential,” “plan,” “target,” or the negative of these terms, and
similar expressions intended to identify forward-looking
statements. These statements reflect our plans, estimates, and
expectations, as of the date of this press release. These
statements involve known and unknown risks, uncertainties and other
factors that could cause our actual results to differ materially
from the forward-looking statements expressed or implied in this
press release. Such risks, uncertainties, and other factors
include, among others, our ability to innovate in the field of
therapeutics, our ability to make future filings and initiate
clinical trials on expected timelines or at all, our ability to
obtain and maintain regulatory approval or clearance of our
products on expected timelines or at all, our plans to research,
develop, and commercialize new products, the unpredictable
relationship between preclinical study results and clinical study
results, our expectations regarding opportunities with current or
future pharmaceutical collaborators, our ability to raise
sufficient capital to achieve our business objectives, and those
risks described in “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in our
Annual Report on Form 10-K for the year ended December 31, 2022
filed with the SEC and other subsequent documents, including
Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor ContactChuck PadalaManaging Director,
LifeSci AdvisorsIR@bioratherapeutics.com(646) 627-8390
Media Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Biora Therapeutics (NASDAQ:BIOR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024